Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ: EOLS )

14.32 +0.36 (+2.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 327,949
Open 14.10
Bid (Size) 14.12 (2)
Ask (Size) 14.59 (2)
Prev. Close 13.96
Today's Range 13.90 - 14.49
52wk Range 9.250 - 17.82
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
From Evolus
Via Business Wire
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
From Evolus
Via Business Wire

Performance

YTD
+28.89%
+28.89%
1 Month
-2.98%
-2.98%
3 Month
+3.77%
+3.77%
6 Month
-9.60%
-9.60%
1 Year
-1.51%
-1.51%

More News

Read More
Breaking Down Evolus: 4 Analysts Share Their Views
Via Benzinga
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
4 Analysts Have This To Say About Evolus
Via Benzinga
A Closer Look at 5 Analyst Recommendations For Evolus
Via Benzinga
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates
Via Benzinga
Crude Oil Down 2%; D.R. Horton Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
Via Investor's Business Daily
Analyst Scoreboard: 4 Ratings For Evolus
Via Benzinga
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus Reports Third Quarter 2024 Results
From Evolus
Via Business Wire
Evolus to Participate in Stifel 2024 Healthcare Conference
From Evolus
Via Business Wire
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
From Evolus
Via Business Wire
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
From Evolus, Inc.
Via Business Wire
Evolus to Report Third Quarter Financial Results on November 6, 2024
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.